Get started

Moderna

Moderna in Trouble - ABUS Wins Lawsuit Tied to COVID-19 DrugArbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. AFTER HOURS BREAKING NEWS Moderna stock tumbled late Thursday after the biotech lost a patent battle that may jeopardize the financial future of its coronavirus vaccine. Moderna (MRNA) challenged patents held by Arbutus Biopharma (ABUS) covering lipid nanoparticle, or LNP, technology. Lipid nanoparticles are the delivery system for messenger RNA drugs, including Moderna's coronavirus vaccine, which is known as mRNA-1273. Despite the company's contention, the ruling could cut into profits on any Moderna drug, including mRNA-1273, says SVB Leerink analyst Mani Foroohar. "Revenue concentration in (the coronavirus vaccine) is a central feature of the investment case for Moderna shares," Foroohar said. "Any meaningful royalty burden could hamper Moderna's pricing flexibility and margin profile vs. other players in the SARS-CoV-2 vaccine market." Foroohar called the decision in Arbutus' favor "a disappointing turn for Moderna." "This decision opens the door to a fascinating (and likely protracted) period of investor controversy and debate around the implications of any potential infringement of claims by Arbutus regarding Moderna's use of Lipid Nanoparticle delivery technology, and any further actions Moderna may take to defend their own (intellectual property) position and freedom to operate," he said. NEWS: www.investors.com Where's ABUS going? To $100.00 ...??? On the monthly chart, it looks like $9.00 might be the next stop..? At this point, I am not sure if there is a top right now for ABUS. The news is huge for ABUS and could entitle ABUS to billions in profits and revenue from the COVID-19 vaccine. Intelligent comments welcome. DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:ABUSLong
by HotCharts
4
MODERNA PUMP AND DUMP SCAMAnother bullshit "vaccine news" to suck in the gullible bulls. 2 Ellipses drawn above were pops, pump and dumps on supposed "good" vaccine news. Insiders (including CFO and CEO) have been dumping stock non-stop. If their "vaccine" is so game changing why are they dumping? Look at candle pattern on day of "vaccine news". We have formed an identical pattern. Open is being used to sell to gullible "investors." S&P 500 response to every vaccine news from this company or Pfizer etc is having less and less durable impact and gains being reversed quickly. S&P wants to go down. As soon as S&P gets down to critical levels and bears look like about to take over a new bullshit "Vaccine" news comes out. S&P is top heavy and wants to go down. Stay short and sell rallies. Cheers! Cyrus
NASDAQ:MRNAShort
by cyrusgr8
15
Moderna Stock Analysis - MRNAThe market is Bullish and the idea, if it is possible, is to invest always in the trend direction. Stochastic is on overbought meaning that the prices might be ready to start the retracement stage. Based on Technical analysis, the idea is to hold and wait the end of the price retracement before going long. Fundametal Analysis Moderna — Moderna shares jumped 10% after the data released by the New England Journal of Medicine showed the company’s coronavirus vaccine candidate, produced neutralizing antibodies in all 45 patients in its early stage human trial. The data shows the vaccine “elicits a robust immune response across all dose levels,” Moderna Chief Medical Officer Tal Zaks said in a statement.
NASDAQ:MRNA
by Mauriello
1
COVID-19 Vaccine, 1st Effective Drug, USA Secures 500,000 DosesHHS secures 500,000 doses of remdesivir. The Trump administration has secured 500,000 doses of remdesivir, the first drug shown to be effective at treating hospitalized coronavirus patients, ensuring these doses will be for U.S. use. This could mean huge profits for GILD. Indicators are starting to turn up, Bullish. Daily Chart is turning Bullish. I think if the stock breaks above the $77.00 range, it's going to spike. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:GILDLong
by HotCharts
4
COVID-19 Play - Closed Over $5.00 - July is Here!On May 15, 2020, Sorrento had this to say about the COVID-19 vaccine they are working on... “We’re actually so impressed with the data,” Ji said. “One of the antibodies is so powerful that at a very low concentration it is able to 100% completely prevent infection or inhibit the infection. In our studies, not even one virus escaped from the antibody.” "Phase 1 trial could start within 1st few days of July" - (It mentions this date in the article) "We anticipate having enough material to start Phase 1 trial in patients in the ICU within two (2) months." - (The article I listed was published in May.) Ji was talking about the COVID-19 vaccine they have been working on with Mount Sinai Health System & the University of Texas Medical Branch which has access to the live virus. Anyone thinking this is not the real deal, you might want to think again. Moderna's stock is sitting at $63.04 (After Hours) - What does Moderna have that Sorrento doesn't have? In the article listed herein, Sorrento said "within 2 months..." We are within those two (2) months now. (End of June or July) Link to article: www.biospace.com Today, SRNE broke out above $5.00 On the daily chart, as of today, the Volume spiked, and the MACD, RSI, Stochastic & Accumulation are all Bullish or trending up Bullish. Is news forthcoming? After watching what the stock price of Moderna did and looking at Sorrento trading at $5.12, to me, the reward far outweighs any risk. Also, I believe Sorrento is waiting for an Emergency Use Label on their COVID-19 test that can give you a positive or negative within 8 minutes. Does Moderna have a test? I don't think so. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
SLong
by HotCharts
3
Bullish Charts - Golden CrossBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts. Daily Chart - Golden Cross Stochastic is moving up, Bullish RSI is crossing center line, Bullish Volume just went green on the daily I think the stock is getting ready to move higher. I also think, BSX is one of the cheapest medical device companies in the industry. Long
NYSE:BSXLong
by HotCharts
SPY-Staying bullish , AlphaOverBeta Market OutlookHello traders, Market Outlook 18.05.2020 This week the stock market returned to positive territory with big technology companies leading the heard. The stock market was up this week with the S&P 500 +3.2% to end the week at 2955.45. Moderna (MRNA) was responsible for most of the earnings this week after announcing they have preliminary results for a coronavirus vaccine, this piece of news jump-started the week as the market made most of this week’s return on this day. The fed chair had its own contribution to the elevated markets reiterating the fed has not finished it’s support of the market and still has ammunition to fight this, this declaration kept the market hovering close to 3000 psychologically critical levels AlphOverBeta Next Week Forecast We have chartered a number of bands for the S&P500, these bands are used for risk control and decision making. 295-310 - This is the best scenario we have for the rest of 2020. This bullish range holds as long as the price is above 295 280-295 - is the current locked trading range, when prices went above 295, it triggered a bullish signal in our systems. 265-280 is the bearish zone. Trade Smartly, Alon, AlphaOverBeta
AMEX:SPYLong
by Alon_AOB
Moderna (MRNA)+300%, is it still possible to earn money or not? Many people are interested in the question, will the shares of Moderna (MRNA) go even higher or not? After all, not so long ago, they were able to show growth of more than 300% in a few months! I will tell you this - if you prefer systematic trading and open your trades on signals, it is not clear at the moment (so we chose a neutral or observational idea). But an even more important question is how to detect the same signal when it appears again on other stocks or instruments? The answer is simple-keep track of those who practice and actually trade and earn money on the exchange. I recommend that you subscribe to several channels of those whose words do not differ from their deeds, as I did in my time - this is the best tool for selecting stocks that are right for you. Well, for everyone who likes to take risks and shorten the action before it gives a clear signal, I will tell you that according to our system of 4 screens, it is "forbidden" to short in the long run.
NASDAQ:MRNA
by ivan_gold_star_
$MRNA FOMO run? Lazy Elliott ForecastI know the news about Moderna is hype right now but technicals are showing a bearish divergence from the RSI. Based on the "Lazy Elliott" Forecast, if you're going to assume this plot to be an impulse wave, wave 3 from this perspective might be complete already. One way to verify is if the price closes below the 161.8% level, it might signal the start of wave 4. Assuming further that wave 4 might be a "simple" correction compared to wave 2 (applying rule of alternation because 2 looks "complex", correct me if I'm wrong) Watch if the price doesn't go beyond the 100% level support. Be open for an extended wave 3 if the hype continues (261.8% above)
NASDAQ:MRNA
by thetradingcomedy
Moderna Therapeutics AnalysisThe uptrend is mainly based on the good news (Fundamental Analysis) and the technical Analysis respects the good news of this stock. Hold before going long - wait the right time to buy, even if we are late on this stock - Target Price of $105 based on Fundamental Analysis: Shares jumped 20% on Monday after the company revealed positive early results from its experimental vaccine for Covid-19, capping off a 309% rally this year. Goldman Sachs lifted its price target for Moderna stock to $105 from $63 on Monday after first trials for its coronavirus drug showed "encouraging" results. Moderna announced Monday that all 45 volunteers in the trial produced antibodies to protect against COVID-19 infection. Shares jumped as much as 39% on the news. The new price target implies a 25% leap from Moderna's price at 12:25 p.m. ET. Analyst Salveen Richter raised the vaccine's probability of success to 75% from 70%, and projected phase-two studies will begin this quarter.
NASDAQ:MRNALong
by Mauriello
MODERNA UPDATEwww.zerohedge.com As I said in the last update of this stock, I do not doubt its bullishness , however, in the short term, under my own experience (as I commented to another TradinView user) when a large unexpected movement occurs, this movement tends to correct itself slightly . Remember the title of this publication. STRADDLE RATIO. In the long term it is likely to be bullish, however a short bearish correction could be expected, and when in doubt, better to trade a bearish leaning straddle (ratio 1 call 2 put).
NASDAQ:MRNA
by Micss22